Evidence map›Paper›PMID 27338364›Full record

ReviewInternational journal of molecular sciences2016

Strategies to Optimize Adult Stem Cell Therapy for Tissue Regeneration.

Shan Liu, Jingli Zhou, Xuan Zhang, Yang Liu, Jin Chen, Bo Hu, Jinlin Song, Yuanyuan Zhang

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shan LiuChongqing Key Laboratory for Oral Diseases and Biomedical Sciences, Chongqing 401147, China. 15823106296@163.com.
Jingli ZhouChongqing Key Laboratory for Oral Diseases and Biomedical Sciences, Chongqing 401147, China. journeyzone@163.com.
Xuan ZhangChongqing Key Laboratory for Oral Diseases and Biomedical Sciences, Chongqing 401147, China. 13677691923@163.com.
Yang LiuChongqing Key Laboratory for Oral Diseases and Biomedical Sciences, Chongqing 401147, China. 13657638643@163.com.
Jin ChenChongqing Key Laboratory for Oral Diseases and Biomedical Sciences, Chongqing 401147, China. ChenJindentistry@163.com.
Bo HuChongqing Key Laboratory for Oral Diseases and Biomedical Sciences, Chongqing 401147, China. huboisthebest@sina.com.
Jinlin SongChongqing Key Laboratory for Oral Diseases and Biomedical Sciences, Chongqing 401147, China. soongjl@163.com.
Yuanyuan ZhangWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center Blvd., Winston-Salem, NC 27157, USA. yzhang@wakehealth.edu.

Funding

Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Stem Cell Therapy Combined with Growth Factors for Stress Urinary IncontinenceR56DK100669 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ZHANG, YUANYUAN NO · 2014 to 2014
$116k
NCATS NIH HHS UL1 TR001420NIDDK NIH HHS R56 DK100669
6 · The paper itself

Abstract

Stem cell therapy aims to replace damaged or aged cells with healthy functioning cells in congenital defects, tissue injuries, autoimmune disorders, and neurogenic degenerative diseases. Among various types of stem cells, adult stem cells (i.e., tissue-specific stem cells) commit to becoming the functional cells from their tissue of origin. These cells are the most commonly used in cell-based therapy since they do not confer risk of teratomas, do not require fetal stem cell maneuvers and thus are free of ethical concerns, and they confer low immunogenicity (even if allogenous). The goal of this review is to summarize the current state of the art and advances in using stem cell therapy for tissue repair in solid organs. Here we address key factors in cell preparation, such as the source of adult stem cells, optimal cell types for implantation (universal mesenchymal stem cells vs. tissue-specific stem cells, or induced vs. non-induced stem cells), early or late passages of stem cells, stem cells with endogenous or exogenous growth factors, preconditioning of stem cells (hypoxia, growth factors, or conditioned medium), using various controlled release systems to deliver growth factors with hydrogels or microspheres to provide apposite interactions of stem cells and their niche. We also review several approaches of cell delivery that affect the outcomes of cell therapy, including the appropriate routes of cell administration (systemic, intravenous, or intraperitoneal vs. local administration), timing for cell therapy (immediate vs. a few days after injury), single injection of a large number of cells vs. multiple smaller injections, a single site for injection vs. multiple sites and use of rodents vs. larger animal models. Future directions of stem cell-based therapies are also discussed to guide potential clinical applications.

Indexed as

RegenerationAdult Stem CellsAnimalsCellular ReprogrammingHumansMesenchymal Stem CellsMesenchymal Stem Cell Transplantationoptimizing strategystem cellsstem cell therapytissue regenerationtissue repair

Identifiers

PMID27338364
PMCPMC4926512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.